The effect of bacteriophage preparations on intracellular killing of bacteria by phagocytes

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Jończyk Matysiak, Ewa ^a   Łusiak Szelachowska, Marzanna ^a   Kłak, Marlena ^a   Bubak, Barbara ^a   Międzybrodzki, Ryszard ^a,b   Weber Dąbrowska, Beata ^a   Zaczek, Maciej ^a   Fortuna, Wojciech ^a   Rogóz, Paweł ^a   Letkiewicz, Sławomir ^a   Szufnarowski, Krzysztof ^a   Górski, Andrzej ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIOPHAGE; BIOLOGICAL THERAPY; CASE CONTROL STUDY; CHEMISTRY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMAN; IMMUNOLOGY; MICROBIOLOGY; MONOCYTE; NEUTROPHIL; PATHOLOGY; PATIENT SAFETY; PHAGOCYTOSIS; PHYSIOLOGY; PRIMARY CELL CULTURE; PROCEDURES; TREATMENT OUTCOME; VIROLOGY;

BACTERIOPHAGES; BIOLOGICAL THERAPY; CASE-CONTROL STUDIES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MONOCYTES; NEUTROPHILS; PATIENT SAFETY; PHAGOCYTOSIS; PRIMARY CELL CULTURE; TREATMENT OUTCOME;

EID: 84953334930     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/482863     Document Type: Article

References (67)

1. W. L. Hazenbos and E. J. Brown, "Phagocytosis: receptors and biology," in Phagocytosis of Bacteria and Bacterial Pathogenicity, J. D. Ernst and O. Stendahl, Eds., vol. 12, pp. 4-53, Cambridge University Press, 2006.
2. E. Metchnikoff, "The nobel lecture," Scandinavian Journal of Immunology, vol. 30, pp. 385-398, 1908.
3. M. B. Hampton, A. J. Kettle, and C. C. Winterbourn, "Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing," Blood, vol. 92, no. 9, pp. 3007-3017, 1998.
4. S. D. Kobayashi, J. M. Voyich, and F. R. DeLeo, "Regulation of the neutrophil-mediated inflammatory response to infection," Microbes and Infection, vol. 5, no. 14, pp. 1337-1344, 2003.
5. O. Nüsse, "Biochemistry of the phagosome: the challenge to study a transient organelle," TheScientificWorldJOURNAL, vol. 11, pp. 2364-2381, 2011.
6. H. A. Verbrugh, R. Peters, P. K. Peterson, and J. Verhoef, "Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes," Journal of Clinical Pathology, vol. 31, no. 6, pp. 539-545, 1978.
7. R. Feld, "The compromised host," European Journal of Cancer and Clinical Oncology, vol. 25, supplement 2, pp. S1-S7, 1989.
8. M.-T. Labro, "Interference of antibacterial agents with phagocyte functions: immunomodulation or immuno-fairy tales?" Clinical Microbiology Reviews, vol. 13, no. 4, pp. 615-650, 2000.
9. G. Gillissen, "Side effects of antibiotics on immune response parameters and their possible implications in antimicrobial chemotherapy," Zentralblatt für Bakteriologie, Mikrobiologie undHygiene. Series A:MedicalMicrobiology, InfectiousDiseases, Virology, Parasitology, vol. 270, no. 1-2, pp. 171-199, 1988.
10. A. A. Khan, T. R. Slifer, and J. S. Remington, "Effect of trovafloxacin on production of cytokines by human monocytes," Antimicrobial Agents and Chemotherapy, vol. 42, no. 7, pp. 1713-1717, 1998.
11. K. Guz and G. Bugla-Ploskonska, "The immunomodulatory and anti-inflammatory properties of different antimicrobial agents," Postepy Higieny iMedycyny Doswiadczalnej, vol. 61, pp. 828-837, 2007.
12. L. Mehes, S. Taskó, A. Szekely, et al., "Phagocytosis and intracellular killing of heterogeneous vancomycin-intermediate Staphylococcus aureus strains," Journal of Medical Microbiology, vol. 61, no. 2, pp. 198-203, 2012.
13. R. Miedzybrodzki, K. Switala-Jelen, W. Fortuna, et al., "Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes," Virus Research, vol. 131, no. 2, pp. 233-242, 2008.
14. R. Miedzybrodzki, J. Borysowski, B. Weber-Dabrowska, et al., "Clinical aspects of phage therapy," Advances in Virus Research, vol. 83, pp. 73-121, 2012.
15. P. Miernikiewicz, K. Dabrowska, A. Piotrowicz, et al., "Cytokine profiles in mice and in human blood treated with phage proteins," PLoS ONE, 2013.
16. A. Przerwa, M. Zimecki, K. Switala-Jelen, et al., "Effects of bacteriophages on free radical production and phagocytic functions," Medical Microbiology and Immunology, vol. 195, no. 3, pp. 143-150, 2006.
17. A. Górski, R. Miedzybrodzki, J. Borysowski, et al., "Phage as a modulator of immune responses: practical implications for phage therapy," Advances in Virus Research, vol. 83, pp. 41-71, 2012.
18. H. P. Buisman, L. F. M. Buys, J. A. M. Langermans, P. J. van den Broek, and R. van Furth, "Effect of probenecid on phagocytosis and intracellular killing of Staphylococcus aureus and Escherichia coli by human monocytes and granulocytes," Immunology, vol. 74, no. 2, pp. 338-341, 1991.
19. A. Böyum, "Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g," Scandinavian Journal of Clinical and Laboratory Investigation, Supplement, vol. 97, pp. 77-89, 1968.
20. P. C. J. Leijh, T. L. Van Zwet, and R. Van Furth, "Effect of concanavalin A on intracellular killing of Staphylococcus aureus by human phagocytes," Clinical and Experimental Immunology, vol. 58, no. 3, pp. 557-565, 1984.
21. W. L. Hand, "Interactions between antimicrobial agents, phagocytic cells and bacteria," Current Medicinal Chemistry: Anti-Infective Agents, vol. 2, no. 1, pp. 73-82, 2003.
22. R. Malka, B. Wolach, R. Gavrieli, E. Shochat, and V. Rom-Kedar, "Evidence for bistable bacteria-neutrophil interaction and its clinical implications," The Journal of Clinical Investigation, vol. 122, no. 8, pp. 3002-3011, 2012.
23. J. L. Copeland, L. R. Karrh, J. McCoy, and J. C. Guckian, "Bactericidal activity of polymorphonuclear leukocytes from patients with severe bacterial infections," Texas Reports on Biology and Medicine, vol. 29, no. 4, pp. 555-562, 1971.
24. E. Roilides, P. Paschalides, A. Freifeld, and P. A. Pizzo, "Suppression of polymorphonuclear leukocyte bactericidal activity by suramin," Antimicrobial Agents and Chemotherapy, vol. 37, no. 3, pp. 495-500, 1993.
25. J. W. Wilson, M. J. Schurr, C. L. LeBlanc, R. Ramamurthy, K. L. Buchanan, and C. A. Nickerson, "Mechanisms of bacterial pathogenicity," PostgraduateMedical Journal, vol. 78, no. 918, pp. 216-224, 2002.
26. P. M. Lepper, T. K. Held, E. M. Schneider, E. Bölke, H. Gerlach, and M. Trautmann, "Clinical implications of antibiotic-induced endotoxin release in septic shock," Intensive CareMedicine, vol. 28, no. 7, pp. 824-833, 2002.
27. M. A. Horwitz, "Phagocytosis of microorganisms," Reviews of Infectious Diseases, vol. 4, no. 1, pp. 104-123, 1982.
28. K. B. Abdul-Majid, P. A. Kenny, and J. J. Finlay-Jones, "The effect of the bacterial product, succinic acid, on neutrophil bactericidal activity," FEMS Immunology and Medical Microbiology, vol. 17, no. 2, pp. 79-86, 1997.
29. N. A. Carlone, A. M. Cuffini, V. Tullio, and G. Cavallo, "Interactions of antibiotics with phagocytes in vitro," Journal of Chemotherapy, vol. 3, pp. 98-104, 1991.
30. W. E. Hauser Jr. and J. S. Remington, "Effect of antibiotics on the immune response," The American Journal of Medicine, vol. 72, no. 5, pp. 711-716, 1982.
31. A. Górski and A. Mularczyk, "Neutrophil functions in renal transplant recipients," Archivum Immunologiae et Therapiae Experimentalis, vol. 26, no. 1-6, pp. 975-979, 1978.
32. A. Kotiranta, M. Haapasalo, K. Kari, et al., "Surface structure, hydrophobicity, phagocytosis, and adherence to matrix proteins of Bacillus cereus cells with and without the crystalline surface protein layer," Infection and Immunity, vol. 66, no. 10, pp. 4895-4902, 1998.
33. C. J. van Oss, D. R. Absolom, and A. W. Neumann, "Interaction of phagocytes with other blood cells and with pathogenic and nonpathogenic microbes," Annals of the New York Academy of Sciences, vol. 416, pp. 332-350, 1983.
34. M. Costa-Hurtado, A. Olvera, V. Martinez-Moliner, et al., "Changes in macrophage phenotype after infection of pigs with Haemophilus parasuis strains with different levels of virulence," Infection and Immunity, vol. 81, no. 7, pp. 2327-2333, 2013.
35. L. Staali, S. Bauer, M. Mörgelin, L. Björck, and H. Tapper, "Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes," Cellular Microbiology, vol. 8, no. 4, pp. 690-703, 2006.
36. J. Dellacasagrande, E. Ghigo, C. Capo, D. Raoult, and J.-L. Mege, "Coxiella burnetii survives in monocytes from patients with Q fever endocarditis: involvement of tumor necrosis factor," Infection and Immunity, vol. 68, no. 1, pp. 160-164, 2000.
37. E. Ghigo, A. Honstettre, C. Capo, J.-P. Gorvel, D. Raoult, and J.-L. Mege, "Link between impaired maturation of phagosomes and defective Coxiella burnetii killing in patients with chronic Q fever," The Journal of Infectious Diseases, vol. 190, no. 10, pp. 1767-1772, 2004.
38. A. P. Levine, M. R. Duchen, and A. W. Segal, "The HVCN1 channel conducts protons across the phagocytic vacuole of neutrophils," European Journal of Clinical Investigation, vol. 44, p. 16, 2014.
39. M. C. de Almeida, A. C. Silva, A. Barral, and M. Barral Netto, "A simple method for human peripheral blood monocyte isolation," Memorias do Instituto Oswaldo Cruz, vol. 95, no. 2, pp. 221-223, 2000.
40. L. Zhou, R. Somasundaram, R. F. Nederhof, et al., "Impact of human granulocyte and monocyte isolation procedures on functional studies," Clinical andVaccine Immunology, vol. 19, no. 7, pp. 1065-1074, 2012.
41. A. Kurzepa-Skaradzinska, M. Lusiak-Szelachowska, G. Skaradzinski, et al., "Influence of bacteriophage preparations on intracellular killing of bacteria by human phagocytes in vitro," Viral Immunology, vol. 26, no. 2, pp. 150-162, 2013.
42. B. Weber-Dabrowska, M. Zimecki, M. Mulczyk, and A. Górski, "Effect of phage therapy on the turnover and function of peripheral neutrophils," FEMS Immunology andMedicalMicrobiology, vol. 34, no. 2, pp. 135-138, 2002.
43. B. R. Tiwari, S. Kim, M. Rahman, and J. Kim, "Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models," Journal of Microbiology, vol. 49, no. 6, pp. 994-999, 2011.
44. Z. Kazmierczak, A. Piotrowicz, B. Owczarek, et al., "Molecular imaging of T4 phage in mammalian tissues and cells," Bacteriophage, vol. 4, no. 2, Article ID e28364, 2014.
45. S. Kaur, K. Harjai, and S. Chhibber, "Bacteriophage-aided intracellular killing of engulfed methicillin-resistant Staphylococcus aureus (MRSA) by murine macrophages," AppliedMicrobiology and Biotechnology, vol. 98, no. 10, pp. 4653-4661, 2014.
46. M. M. Salgado, A. C. Pignatari, and R. Bellinati-Pires, "Phagocytosis and killing of epidemic methicillin-resistant Staphylococcus aureus by human neutrophils and monocytes," Brazilian Journal of Infectious Diseases, vol. 8, no. 1, pp. 80-89, 2004.
47. C. A. Arias and B. E. Murray, "Antibiotic-resistant bugs in the 21st century-a clinical super-challenge," The New England Journal of Medicine, vol. 360, no. 5, pp. 439-443, 2009.
48. J. B. Deris, M. Kim, Z. Zhang, et al., "The innate growth bistability and fitness landscapes of antibiotic-resistant bacteria," Science, vol. 342, no. 6162, Article ID1237435, 2013.
49. C. Wenisch, B. Parschalk, M. Hasenhundl, E. Wiesinger, and W. Graninger, "Effect of cefodizime and ceftriaxone on phagocytic function in patients with severe infections," Antimicrobial Agents and Chemotherapy, vol. 39, no. 3, pp. 672-676, 1995.
50. F. T. Zagury, "The role of antibiotics in immunosuppressive diseases," Advances in Pork Production, vol. 17, pp. 161-167, 2006.
51. M. P. Francino and A. Moya, "Effects of antibiotic use on the microbiota of the gut and associated alterations of immunity and metabolism," EMJ Gastroenterology, vol. 1, pp. 74-80, 2013.
52. K. Brandl, G. Plitas, C. N. Mihu, et al., "Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits," Nature, vol. 455, no. 7214, pp. 804-807, 2008.
53. B. Kwiatkowska, M. Maslinska, M. Przygodzka, J. Dmowska-Chalaba, J. Dabrowska, and K. Sikorska-Siudek, "Immune system as a new therapeutic target for antibiotics," Advances in Bioscience and Biotechnology, vol. 4, no. 4, pp. 91-101, 2013.
54. D. B. Wiest, J. B. Cochran, and F. W. Tecklenburg, "Chloramphenicol toxicity revisited: a 12-year-old patient with a brain abscess," The Journal of Pediatric Pharmacology and Therapeutics, vol. 17, no. 2, pp. 182-188, 2012.
55. A. Górski, J. Borysowski, R. Miedzybrodzki, and B. Weber-Dabrowska, "Bacteriophages in medicine," in Bacteriophage:, Genetics and Microbiology, S. McGrath and D. van Sinderen, Eds., pp. 125-158, Caister Academic Press, Norfolk, UK, 2007.
56. G. W. Hanlon, "Bacteriophages: an appraisal of their role in the treatment of bacterial infections," International Journal of Antimicrobial Agents, vol. 30, no. 2, pp. 118-128, 2007.
57. E. Kutter, S. Kuhl, Z. Alavidze, and B. G. Blasdel, "Phage therapy: bacteriophages as natural, self-limiting antibiotics," in Textbook of Natural Medicine, J. E. Pizzorno and M. T. Murray, Eds., chapter 112, pp. 945-956, Elsevier Churchill Livingstone, 4th edition, 2012.
58. E. Kutter, D. De Vos, G. Gvasalia, et al., "Phage therapy in clinical practice: treatment of human infections," Current Pharmaceutical Biotechnology, vol. 11, no. 1, pp. 69-86, 2010.
59. A. Górski, R. Miedzybrodzki, J. Borysowski, et al., "Bacteriophage therapy for the treatment of infections," Current Opinion in Investigational Drugs, vol. 10, no. 8, pp. 766-774, 2009.
60. J. Borysowski, R. Miedzybrodzki, and A. Górski, PhageTherapy: Current Research and Applications, Caister Academic Press, Hardback, 2014.
61. S. Chhibber, T. Kaur, and S. Kaur, "Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections," PLoSONE, vol. 8, no. 2, Article IDe56022, 2013.
62. M. Lusiak-Szelachowska, M. Zaczek, B. Weber-Dabrowska, et al., "Phage neutralization by sera of patients receiving phage therapy," Viral Immunology, vol. 27, no. 6, pp. 295-304, 2014.
63. J. Borysowski and A. Górski, "Is phage therapy acceptable in the immunocompromised host?" International Journal of Infectious Diseases, vol. 12, no. 5, pp. 466-471, 2008.
64. D. A. C. Stapels, K. X. Ramyar, M. Bischoff, et al., "Staphylococcus aureus secretes a unique class of neutrophil serine protease inhibitors," Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 36, pp. 13187-13192, 2014.
65. J. Borysowski, P. Wierzbicki, D. Klosowska, G. Korczak-Kowalska, B. Weber-Dabrowska, and A. Górski, "The effects of T4 andA3/R phage preparations onwhole-bloodmonocyte and neutrophil respiratory burst," Viral Immunology, vol. 23, no. 5, pp. 541-544, 2010.
66. W. A. Gorczyca, M. Mitkiewicz, J. Siednienko, et al., "Bacteriophages decrease activity of NFκB induced in human mononuclear cells by human herpesvirus-1," in Proceedings of the 13th International Congress of Immunology, Rio de Janeiro, Brazil, August 2007.
67. R. Miedzybrodzki, W. Fortuna, B. Weber-Dabrowska, and A. Górski, "A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses," Clinical and Experimental Medicine, vol. 9, no. 4, pp. 303-312, 2009.